Huons Meditech Accelerates Overseas Marketing
Huons Meditech Accelerates Overseas Marketing
- Participation in SIU 2024 and ICAP 2024... Efforts to Expand Global Influence -
▲ Huons Meditech participated in the "SIU 2024" held in New Delhi, India, and introduced the lithotripter "URO-UEMXD." Visitors are taking photos after the announcement of the theme of "ESWL's Latest Trends." LEE Jin-suk, CEO of Huons Meditech, is on the left side of the front row of the photo
Huons Meditech Co., Ltd., under the leadership of CEO LEE Jin-suk, recently announced its participation in the 2024 Congress of the Société Internationale d’Urologie (SIU 2024) held in New Delhi, India. Through this event, the company sought to demonstrate its advanced technology and strengthen its competitive presence on the global stage.
SIU, established in 1907, is one of the most distinguished international platforms focused on urological diseases and treatments, drawing thousands of experts from over 100 countries each year. Attendees engage in sessions and exhibitions that discuss the latest technological advancements and treatment methods shaping global urology.
At SIU 2024, Huons Meditech showcased its URO-UEMXD, an extracorporeal shock wave lithotripter (ESWL) that combines a shock wave head and an inline ultrasound probe, setting it apart from traditional X-ray-based devices. This innovative approach enables both diagnosis and treatment of opaque and non-opaque urinary stones through ultrasound, allowing for heightened precision and minimizing reliance on X-ray imaging. The URO-UEMXD, developed in collaboration with India’s Vasu Group, was well-received at the event, underscoring Huons Meditech’s intention to capture a substantial portion of the global urology market.
Further enhancing the company’s impact, Professor Yoon Hana, Korea’s first female urologist, presented on “The Current Trend of ESWL in Urolithiasis.” Her discussion emphasized the URO-UEMXD’s clinical efficacy and safety, supporting these claims with research findings that highlighted improved treatment outcomes and patient comfort.
In addition to SIU 2024, Huons Meditech participated in the ICAP 2024 (International Congress of ASLS & Perdaweri Banten) in Jakarta, Indonesia. Here, the focus shifted to strengthening the company’s influence in the global beauty device market, underscoring Huons Meditech’s diverse portfolio and international ambitions.
LEE Jin-suk (CEO) noted that participating in these prominent international conferences has provided Huons Meditech with valuable exposure and networking opportunities, furthering the company’s reach in both the Indian and Indonesian markets. Emphasizing collaboration with global partners, he expressed the company’s commitment to actively expand its market share through strategic partnerships and continued innovation.
▲ Huons Meditech participated in the "ICAP 2024" held in Jakarta, Indonesia, and is conducting promotional activities by informing visitors of product excellence.
Huons Meditech offers a new paradigm for ESWT in urology
Huons Meditech drives global growth, participating in medical device symposiums in AU&US
Huons Meditech to showcase at Healthcare Trade Fair ‘Hospitalar 2025’ in Brazil
Huons Meditech receives Taiwan FDA approval for gynecological drug delivery system 'Jill'SOF'
Huons Group participates ‘Dubai Derma 2025’ for efforts to maximize sales
Huons Meditech officially launches Extracorporeal Shock Wave Therapy device ‘IMPO88 Plus’ for Erectile Dysfunction - Proven effect on Chronic Prostatitis/Chronic Pelvic Pain Syndrome Treatment -
Huons Meditech Showcases Innovative Medical Devices at ‘KIMES 2025’
Huons Meditech Showcases at Arab Health 2025 in Dubai
Huons Meditech Launches ‘Premium 9-Pin Needle 31G’ for Skin Booster Treatments
Huons Meditech Showcases Expertise at the ‘Society of Female Functional Urology and Sexual Medicine International Seminar’
Huons Meditech Accelerates Overseas Marketing
Huons Meditech Showcases Key Products at FIME 2024 in Florida